



**GENPHARMASEC
LIMITED**

CIN : L24231MH1992PLC323914

(Formerly known as Generic Pharmasec Limited)



Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101



+91- 86555 50242



compliance@genpharmasec.com
info@genpharmasec.com



www.genpharmasec.com

Date: 30th May, 2022

To,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Subject: - Annual Secretarial Compliance Report for the year ended March 31, 2022.
Scrip Code: 531592

Dear Sir(s),

Pursuant to Regulation 24A of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDI/27/2019 dated February 8, 2019 we are enclosing herewith the Annual Secretarial Compliance Report issued by Priya Shah & Associates, Practicing Company Secretaries for the year ended March 31, 2022.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Genpharmasec Limited
(Formerly known Generic Pharmasec Limited)

Ulhas Narayan Deosthale
Whole Time Director
DIN: 09215291



Encl: As above



PRIYA SHAH & ASSOCIATES
PRACTISING COMPANY SECRETARY

B-2/34, 2nd Floor Meghdoot CHS, Behind Star Apt., S.V. Road, Borivali (W), Mumbai - 400 092.
Mob.: +91 9987 999 482 | Email: cspriyashah1@gmail.com

**SECRETARIAL COMPLIANCE REPORT OF THE GENPHARMASEC LIMITED
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED) FOR THE YEAR ENDED
31ST MARCH 2022**

To,
The Members,
Genpharmasec Limited,
(Formerly Known as Generic Pharmasec Limited)
Office No. 104 & 105 (1st Floor),
Gundecha Industrial Premises Co-Operative Society Ltd.,
Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101

I, Priya Shah, Proprietor of Priya Shah & Associates, Practising Company Secretaries, having office at B-2/34, Meghdoot CHS, near tehsildar office, natakwala lane, Borivali (w), Mumbai 400092, have examined the following as under:

- a) All the documents and records made available to me and explanations provided by GENPHARMASEC LIMITED (Formerly Known as Generic Pharmasec Limited)
- b) The filings/ submissions made by the listed entity to the stock exchange
- c) Website of the listed entity
- d) And any other document/filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 31st March 2022 in respect of compliance with the provisions of:

- a) The Securities and Exchange Board of India Act, 1992 (SEBI Act) and the Regulations, circulars, guidelines issued there under; and
- b) The Securities Contracts (Regulations) Act, 1956 (SCRA), rules made there under and the Regulations, circulars, guidelines issued there under by the Securities and Exchange Board of India (SEBI)

The specific Regulations, whose provisions and the circulars/ guidelines issued there under, have been examined, include-

- a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations);

- b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not Applicable to the Company during the Audit Period);
- c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011;
- d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; (Not Applicable to the Company during the Audit Period);
- e) Securities and Exchange Board of India (Shares Based Employee Benefits) Regulations, 2014; (Not Applicable to the Company during the Audit Period);
- f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not Applicable to the Company during the Audit Period);
- g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013; (Not Applicable to the Company during the Audit Period);
- h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- i) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018;

and circulars/ guidelines issued thereunder;

and based on the above examination, I hereby report that, during the Review Period:

- a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued there under, except in respect of matters specified below:

Sr. No	Compliance Requirement (Regulations / circulars / guidelines including specific Clause)	Deviations	Observations/ Remarks of the Practicing Company Secretary
NIL			

- b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued there under in so far as it appears from my examination of those records.
- c) As confirmed by the management, there were no actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued there under:

Sr. No.	Action taken	Details of Violation	Details of action taken E.g. fines, warning letter, debarment etc	Observations/ remarks of the Practising Company Secretary, if any.
NIL				

d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations of the Practising Company Secretary in the previous reports (for the year ended March 2021)	Observation made in the Secretarial Compliance Report for the Year ended	Action taken by the listed Entity, if any	Comments of the Practising Company Secretary on the actions taken by the Listed entity
NIL				

For Priya Shah & Associates
Practising Company Secretary



Priya Shah

Date: 30th May, 2022
Place: Mumbai
ICSI UDIN: F010763D000424220
Peer Review Certificate No: 1390/2021

Priya Shah
Proprietor
COP.: 21827
FCS: 10763